Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 20, 2009, Pages 5898-5901

  Menear, Keith A ^a   Gomez, Sylvie ^a   Malagu, Karine ^a   Bailey, Christine ^a   Blackburn, Kristel ^a   Cockcroft, Xiao Ling ^a   Ewen, Sally ^a   Fundo, Alexandra ^a   Gall, Armelle Le ^a   Hermann, Gesine ^a   Sebastian, Luisa ^a   Sunose, Mihiro ^a   Presnot, Thomas ^a   Torode, Eleanor ^a   Hickson, Ian ^a   Martin, Niall M B ^a   Smith, Graeme C M ^a,b   Pike, Kurt G ^b  

^a KuDOS Pharmaceuticals Ltd   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Kinase inhibitors; Mammalian target of rapamycin; mTOR; Phosphatidylinositol 3 kinase; PI3K

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOTRANSFERASE INHIBITOR; PYRIMIDINE DERIVATIVE; TRIAZINE DERIVATIVE;

ARTICLE; CELL ACTIVITY; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; MOLECULAR WEIGHT; NONHUMAN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MORPHOLINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

MAMMALIA;

EID: 70349199015     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.08.069     Document Type: Article

References (21)

1. Huang S., and Houghton P.J. Curr. Opin. Pharmacol. 3 (2003) 371
2. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., and Workman P. Curr. Opin. Pharmacol. 8 (2008) 393
3. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., and Schreiber S.L. Nature 369 (1994) 756
4. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., and Snyder S.H. Cell 78 (1994) 35
5. Abraham R.T. Curr. Opin. Immunol. 8 (1996) 412
6. Fingar D.C., Salama S., Tsou C., Harlow E., and Blenis J. Gene Dev. 16 (2002) 1472
7. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., and Blenis J. Mol. Cell. Biol. 24 (2004) 200
8. Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence Jr. J.C., and Abraham R.T. EMBO J. 15 (1996) 5256
9. Sarbassov D.D., Ali S.M., and Sabatini D.M. Curr. Opin. Cell Biol. 17 (2005) 596
10. Edinger A.L., Linardic C.M., Chiang G.G., Thompson C.B., and Abraham R.T. Cancer Res. 63 (2003) 8451
11. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., and Gray N.S. J. Biol. Chem. 284 (2009) 8023
12. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z., Ruggero D., and Shokat K.M. PLoS Biol. 7 (2009) 371
13. Hollick J.J., Rigoreau L.J.M., Cano-Soumillac C., Cockcroft X., Curtin N.J., Frigerio M., Golding B.T., Guiard S., Hardcastle I.R., Hickson I., Hummersone M.G., Menear K.A., Martin N.M.B., Matthews I., Newell D.R., Ord R., Richardson C.J., Smith G.C.M., and Griffin R.J. J. Med. Chem. 50 (2007) 1958
14. Lipinski C.A., Lombardo F., Dominy B.W., and Feency P.J. Adv. Drug Delivery Rev. 23 (1997) 3
15. Inhibition of mTOR kinase was assayed using full-length mTOR (extracted from HeLa cytoplasmic extract by immunoprecipitation) with a recombinant 4E-BP1 protein substrate and an ATP concentration of 50 μM. Detection of phosphorylated product through an ELISA format was essentially as described in Ref. 8 Figures quoted are the mean of at least 2 determinations and variability around the mean was <50%.
16. mTOR Kinase inhibition experiments were conducted at increasing concentrations of inhibitor (1) (50, 100, 200, 350, 500 nM) in varying concentrations of ATP (10-100 μM). The data was plotted using a Lineweaver-Burke double reciprocal plot and revealed characteristic behaviour of competitive inhibition.
17. Verheijen J.C., and Zask A. Drugs Future 32 (2007) 537
18. Hickson I., Zhao Y., Richardson C.J., Green S.J., Martin N.M., Orr A.I., Reaper P.M., Jackson S.P., Curtin N.J., and Smith G.C. Cancer Res. 64 (2004) 9152
19. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., and Williams R.L. Mol. Cell. 6 (2000) 909
20. Monolayers of MDCKII (Madin Darby Canine Kidney Cells) cells transfected with the human MDR1 (Multi-Drug Resistance 1) transporter protein were cultured in transwells and used to study the permeability and efflux potential of compounds (17) and (19) at a concentration of 10 μM. Since neither compound showed significant levels of efflux in this assay, the Papp in the A to B direction is considered to provide a measure of the passive permeability of the compounds in these cells.
21. Keogh J.P., and Kunta J.R. Eur. J. Pharm. Sci. 27 (2006) 543